Emergent BioSolutions
Specialized products to healthcare providers and governments to address. Learn more
Launch date
Employees
Market cap
€367m
Enterprise valuation
€1.1b (Public information from Sep 2024)
Share price
$6.99 EBS
Street Maryland (HQ)
Financials
Estimates*
USD | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
---|---|---|---|---|---|---|---|
Revenues | 1.6b | 1.8b | 1.1b | 1.0b | 1.1b | 1.1b | 1.1b |
% growth | 41 % | 15 % | (37 %) | (9 %) | 3 % | 8 % | - |
EBITDA | 553m | 514m | (34.4m) | (67.5m) | 145m | 57.6m | - |
% EBITDA margin | 36 % | 29 % | (3 %) | (7 %) | 14 % | 5 % | - |
Profit | 305m | 231m | (224m) | (760m) | (263m) | (110m) | (112m) |
% profit margin | 20 % | 13 % | (20 %) | (74 %) | (25 %) | (10 %) | (10 %) |
EV / revenue | 3.2x | 1.4x | 1.2x | 0.8x | 0.5x | 0.7x | 0.7x |
EV / EBITDA | 9.1x | 5.1x | -39.3x | -12.9x | 3.8x | 13.5x | - |
R&D budget | 235m | 234m | 193m | 111m | - | - | - |
R&D % of revenue | 15 % | 13 % | 17 % | 11 % | - | - | - |
Source: Dealroom estimates
Date | Investors | Amount | Round |
---|---|---|---|
- | N/A | - | |
N/A | N/A | IPO | |
N/A | $2.0m | Post IPO Debt | |
N/A | $20.0m | Grant | |
$14.5m | Grant | ||
* | N/A | Grant | |
* | N/A | N/A | Post IPO Debt |
* | N/A | $250m | Post IPO Debt |
Total Funding | €31.4m |
Related Content
Recent News about Emergent BioSolutions
EditMore about Emergent BioSolutions
EditAt Emergent, we develop, manufacture, and deliver protections against public health threats. For more than two decades, we’ve been at work defending people from things we hope will never happen — so that we’re prepared, just in case they ever do.
Please note: It has come to our attention that there may be people posing as Emergent recruiters and hiring managers online, offering fraudulent opportunities to job seekers. Emergent will never ask for any financial commitment from a candidate as a pre-employment requirement. Learn more about recruitment fraud and how to protect yourself here: https://bit.ly/recruitment-fraud
Tech stack
Tech stackLearn more about the technologies and tools that this company uses.
Investments by Emergent BioSolutions
EditACQUISITION by Emergent BioSolutions Aug 2018
ACQUISITION by Emergent BioSolutions Dec 2013
ACQUISITION by Emergent BioSolutions Jun 2005